Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment

被引：2
|
作者：
Yurttutan, Sadik [1 ]
Gullu, Utku Ufuk [2 ]
Ipek, Sevcan [3 ]
机构：
[1] Kahramanmaras Sutcu Imam Univ, Div Neonatol, Dept Pediat, Fac Med, Avsar Campus, TR-46100 Kahramanmaras, Turkey
[2] Kahramanmaras Sutcu Imam Univ, Div Pediat Cardiol, Dept Pediat, Fac Med, Kahramanmaras, Turkey
[3] Kahramanmaras Sutcu Imam Univ, Div Pediat Intens Care Unit, Dept Pediat, Fac Med, Kahramanmaras, Turkey
来源：
INTERNAL AND EMERGENCY MEDICINE | 2021年 / 16卷 / 04期
关键词：
D O I：
10.1007/s11739-021-02663-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1101 / 1103
页数：3
相关论文
共 50 条
  • [31] Tocilizumab and corticosteroids for COVID-19 treatment in elderly patients
    Balena, Flavia
    Bavaro, Davide Fiore
    Fabrizio, Claudia
    Bottalico, Irene Francesca
    Calamo, Angela
    Santoro, Carmen Rita
    Brindicci, Gaetano
    Bruno, Giuseppe
    Mastroianni, Antonio
    Greco, Sonia
    Buccoliero, Giovanni Battista
    Carbonara, Sergio
    Lo Caputo, Sergio
    Santantonio, Teresa
    Monno, Laura
    Angarano, Gioacchino
    Saracino, Annalisa
    JOURNAL OF GERONTOLOGY AND GERIATRICS, 2020, 68 (04): : 197 - 203
  • [32] Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
    Rodriguez-Bano, Jesus
    Pachon, Onimo
    Carratala, Jordi
    Ryan, Pablo
    Jarrin, Inmaculada
    Yllescas, Maria
    Ramon Arribas, Jose
    Berenguer, Juan
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (02) : 244 - 252
  • [33] Anakinra for severe forms of COVID-19: a cohort study
    Huet, Thomas
    Beaussier, Helene
    Voisin, Olivier
    Jouveshomme, Stephane
    Dauriat, Gaelle
    Lazareth, Isabelle
    Sacco, Emmanuelle
    Naccache, Jean-Marc
    Bezie, Yvonnick
    Laplanche, Sophie
    Le Berre, Alice
    Le Pavec, Jerome
    Salmeron, Sergio
    Emmerich, Joseph
    Mourad, Jean-Jacques
    Chatellier, Gilles
    Hayem, Gilles
    LANCET RHEUMATOLOGY, 2020, 2 (07): : E393 - E400
  • [34] Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study
    Kardos, Zsofia
    Szabo, Miklos
    Barath, Zsuzsanna
    Miksi, Agnes
    Olah, Csaba
    Kozma, Adam
    Gergely, Jozsef A.
    Csanky, Eszter
    Szekanecz, Zoltan
    BIOMEDICINES, 2023, 11 (02)
  • [35] USE OF BARICITINIB AND TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 IN HOSPITALIZED PATIENTS
    Xibille Friedmann, D. X.
    Carrillo Vazquez, S. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 899 - 900
  • [36] Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
    Roddy, John
    Wells, Daniel
    Schenck, Katharine
    Santosh, Shrihari
    Santosh, Sadashiv
    CRITICAL CARE EXPLORATIONS, 2022, 4 (05)
  • [37] Relative bradycardia in patients with moderate-to-severe COVID-19: a retrospective cohort study
    Takashi Yoshizane
    Atsushi Ishihara
    Teruki Mori
    Akifumi Tsuzuku
    Jun Suzuki
    Toshiyuki Noda
    SN Comprehensive Clinical Medicine, 4 (1)
  • [38] Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19
    Reid, Nancy Kierstin
    Joyner, Kayla Rena
    Lewis-Wolfson, Temeka Dawn
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (07) : 769 - 775
  • [39] Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study
    Rossi, Benjamin
    Nguyen, Lee S.
    Zimmermann, Philippe
    Boucenna, Faiza
    Dubret, Louis
    Baucher, Louise
    Guillot, Helene
    Bouldouyre, Marie-Anne
    Allenbach, Yves
    Salem, Joe-Elie
    Barsoum, Paul
    Oufella, Arezki
    Gros, Helene
    PHARMACEUTICALS, 2020, 13 (10) : 1 - 11
  • [40] BARICITINIB VERSUS TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19
    Lewis-Wolfson, Temeka
    Joyner, Kayla
    Reid, Nancy
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 191 - 191
12345